Research
Hormonal
Semaglutide 2.4 mg weekly reduces major adverse cardiovascular events (MACE) by 20% in people with BMI ≥27 kg/m² and pre-existing cardiovascular disease, independent of diabetes status.
If you are overweight (BMI 27+) and have heart disease, ask your doctor about semaglutide. It has been shown to reduce the risk of heart attack, stroke, or death from heart causes by 20%. This benefit exists even if you don't have diabetes.
StrongSupportsVERY_HIGH confidence
This trial is important in being the first RCT of an obesity treatment to show a reduction in major adverse cardiovascular events (MACE). In over 17,500 people with BMI (cid:1)27 kg/m2 and pre-existing cardiovascular disease, treatment with semaglutide led to a 20% reduction (hazard ratio, 0.80; 95% CI 0.72 to 0.90; P < 0.001) in a composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke
Why this rating
Based on SELECT trial, N>17,500, long duration (40 months).
Source
Obesity medications: A narrative review of current and emerging agents
Qi Q et al. · Osteoarthritis and Cartilage Open · 2024
DOI 10.1016/j.ocarto.2024.100472
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- New generation incretin analogues (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) produce sustained mean weight reductions of 15-20% in adults with BMI ≥27 kg/m², significantly outperforming older agents and lifestyle interventions alone.Strong
- Tirzepatide (5-15 mg weekly) achieves mean weight loss of 15-21% in adults with BMI ≥27 kg/m², demonstrating superior efficacy compared to placebo and potentially other GLP-1 agonists.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →